Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Quadrivalent HPV Vaccine (Hansenula Polymorpha) in Chinese Females
NCT03085381Phase 1Completed
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CERVAVAC in human papillomavirus infection (2 arms), sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoints: Systemic and local adverse events and Primary Immunogenicity. Started Dec 2016; status: completed.
02
Drugs
CERVAVAC
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03085381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085381.